409A Valuation for Biotech Companies: Why the Inputs Are Different
Author: Redwood Valuation Content Team
Published: September 23, 2026
Biotech is a broad category. Therapeutics developers, medical-device companies, diagnostics companies, and other biotech businesses can follow very different development and regulatory paths. This article focuses on pre-revenue therapeutics companies, which follow the same §409A valuation rules as other private companies but can have substantially different valuation inputs.
For these companies, revenue may be years away, clinical and regulatory milestones can move value sharply, internally developed R&D costs are generally expensed under U.S. GAAP, and valuation evidence may include both equity financings and licensing arrangements. If you're responsible for your company's 409A process, the key questions are what evidence supports current value, how milestone-driven outcomes should affect allocation across the cap table, and when new information requires the company to revisit an existing valuation.
Why the Inputs Are Different for Pre-Revenue Therapeutics Companies
For the therapeutics companies discussed here, the main valuation differences come from three features: little or no revenue, research programs that may be major sources of enterprise value, and milestones that can materially change the company's risk profile. The table below summarizes those inputs alongside a more conventional venture-backed company.
| Value Driver | Typical Venture-Backed Startup | Pre-Revenue Therapeutics Company |
|---|---|---|
| Revenue | May be present and growing; can support multiples and forecasts | Often none for years |
| How value changes | Can reflect both operating progress and discrete events | Often has major step changes as programs read out |
| Primary asset | May include customers, contracts, product, technology, and team | Research programs and related intellectual property can be major value drivers |
| Most recent value signal | Often a priced equity round | A priced round may be important; licensing arrangements can provide additional evidence |
| Time to liquidity | Company-specific | Often tied closely to clinical, regulatory, financing, and strategic outcomes |
Between major readouts, a pre-revenue therapeutics company may show limited operating change even though new clinical or regulatory information can move enterprise value sharply. A significant result can change the perceived probability of technical or commercial success. It can also affect expected financing needs, partnering prospects, and, depending on the event, the expected timing of commercialization. Not every milestone changes all of those inputs, so the valuation effect is event- and company-specific.
The table's asset and transaction-evidence rows raise two different issues. If an unapproved research program is a major source of enterprise value, the valuation has to reflect that program's economics. Internally developed R&D costs are generally expensed as incurred under U.S. GAAP, subject to applicable exceptions, so the balance sheet can omit much of the internally created economic value associated with successful research. An out-licensing agreement creates a different issue: it can provide information about program economics and risk, but it is not itself a priced transaction in the company's equity.
Valuation Approaches for a Pre-Revenue Therapeutics Company
With no revenue to capitalize, a pre-revenue therapeutics company can be difficult to value using conventional revenue or earnings multiples. Section 409A still requires a reasonable valuation method to consider all information material to value. Depending on the facts, that may include asset values, anticipated cash flows, comparable-company evidence, and recent arm's-length transactions. A recent financing may provide an important calibration point within that broader analysis. When the transaction is no longer sufficiently informative, the analysis often needs to reflect current company and market facts rather than simply carry the old price forward.
A backsolve, often called the Subject Company Transaction Method, starts with a transaction in the company's own securities and solves for the equity value consistent with the observed price. OPM can be used as part of that calibration. In an OPM-based backsolve, OPM allocates value across the capital structure while the model solves for the equity value that reproduces the financing price. Backsolve and OPM are related for these purposes, but they are distinct valuation concepts and don't have to be used together in every case.
Even when a clinical-stage therapeutics company has a recent financing, the transaction may not provide a clean current calibration point. These are considerations an appraiser weighs, not disqualifiers:
Rounds may be spaced far enough apart that the transaction is stale relative to the valuation date.
Financings are frequently tranched against development milestones, so the headline round isn't necessarily a single clean current price signal.
Strategic and pharmaceutical investors may participate on terms that include commercial or informational benefits alongside the equity purchase.
A company may have relied for a substantial period on non-dilutive capital without a new priced round.
Grant funding, government awards, and milestone payments change the company's cash position. Depending on their nature, they may also change program risk or the probability of success. They may not by themselves provide a direct price for the company's equity. A backsolve requires a transaction in the company's securities. If these items are not part of such a transaction, they cannot serve as the observed security price, although they remain relevant facts in determining current value.
Licensing agreements provide a different kind of evidence. An out-license with an upfront payment, milestones, and royalties can impact value by changing expected cash flows, risk, and the probability of commercial success. But the payments are not automatically added dollar-for-dollar to equity value because the company has also transferred economic rights. The valuation therefore has to consider both the value received and the rights given up. It also has to consider whether the expected agreement was already reflected in a prior financing.
If no recent transaction is sufficiently informative, there's still no single prescribed fallback. A calibrated roll-forward starts with a prior transaction or valuation and updates it for company and market developments between that date and the current valuation date. Depending on the facts, income, market, or asset approaches may also be appropriate. Relief-from-royalty is an intangible-asset valuation method that may be used for valuing IP and in other contexts. In simplified terms, it estimates the value of owning an asset by reference to the royalty payments the owner avoids by not having to license that asset from someone else. Using it to value a particular asset does not make it a default §409A method for valuing the company's equity.
| Approach | When it fits | What it needs |
|---|---|---|
| Income approach | When company-specific cash flows and development probabilities can be supported; for drug developers, this may include rNPV or another DCF | Forecast cash flows, development timelines, probability assumptions, and discount rates |
| Market approach | When a subject-company transaction or sufficiently comparable company or transaction evidence is relevant to current value; comparability can be difficult for early-stage companies | Transaction terms, a full capital structure, comparable data, and analysis of changes since the transaction |
| Asset approach | When identifiable assets or development costs provide meaningful evidence; cost-to-recreate can be informative in some very early-stage settings | Asset information, development or recreation costs, and fact-specific adjustments |
These are valuation approaches. Once total equity value or scenario values have been established, a separate allocation step determines how that value is distributed across the cap table. That's where OPM, scenario-based analysis, and hybrid methods come in.
OPM, the Scenario-Based Method (SBM), and Binary Milestones
A traditional single OPM models a smooth distribution of future equity values over the expected period to liquidity. That can be a harder fit when a company's value is expected to jump around a major binary milestone.
The OPM treats each class of security as an option-like claim on the company's total equity value. It distributes value across breakpoints derived from the rights and preferences in the capital structure. Our article on the Option Pricing Model covers the mechanics and the inputs in full.
Business-development work may also use “real options” or risk-adjusted NPV analyses. Those methods model the economics and development risk of a drug asset. OPM, by contrast, is a Black-Scholes-based framework for allocating company equity among security classes based on their rights and preferences. In other words, rNPV can help address what a drug program is worth, while OPM addresses how equity value is allocated across the cap table.
A Phase 3 topline readout or a regulatory decision is a discrete event, not a gradual drift. A single smooth-distribution model may not adequately capture the resulting range of outcomes when the milestone can cause a sharp change in enterprise value. That's a question of fit, not a defect in the model.
The AICPA's December 2025 working draft on private-company equity valuation addresses fair-value measurement for financial reporting, not §409A tax guidance. That distinction matters because §409A uses fair market value, a tax-law standard, rather than ASC 820 fair value.
In paragraph 6.47, the AICPA working draft explains that a single OPM may not capture jumps in enterprise value when a pre-commercial biotech company reaches or fails to reach key clinical milestones. It points to hybrid modeling for that kind of multimodal distribution. That's useful modeling guidance, not a §409A rule.
The AICPA working draft uses the term scenario-based method (SBM) for discrete-scenario analysis. PWERM uses that scenario logic by modeling discrete exit scenarios, assigning each a probability, and weighting the resulting per-share values accordingly. Named outcomes map more naturally onto "approved" and "not approved" than a single continuous distribution does. Our article on the PWERM method covers how the scenarios get built.
A hybrid approach combines elements of both methods. It can model a dominant near-term binary catalyst as discrete scenarios while using OPM to allocate value within one or more of those scenarios. That structure can reflect a major near-term event while preserving OPM allocation where it fits. The AICPA working draft specifically describes this type of hybrid structure.
Scenario-based analysis isn't automatically preferable for a clinical-stage therapeutics company. OPM can remain appropriate when the facts and assumptions support it.
No §409A regulation prescribes OPM, SBM/PWERM, or a hybrid as the required allocation method. The appropriate method depends on the facts and assumptions that best reflect the company's expected outcomes, not simply on its status as a therapeutics company.
A wide spread between the preferred financing price and the modeled common value is a valuation result, not a target to select in advance. The result can change with the capital structure, liquidation preferences, expected time to liquidity, and other valuation assumptions. Published rules of thumb stating that biotech common should equal a fixed percentage of preferred should therefore be treated cautiously unless the source and methodology are transparent. The company's own rights, preferences, timing, and valuation assumptions should drive the result.
What Counts as a Material Event for a Pre-Revenue Therapeutics Company
A 409A valuation doesn't automatically remain usable for twelve months. It can stop being reasonable earlier if later information may materially affect value. Under Treas. Reg. §1.409A-1(b)(5)(iv)(B)(1), a previously calculated value is not reasonable at a later date if it fails to reflect such information or if its valuation date is more than twelve months earlier than the date for which the value is used. The independent-appraisal presumption has its own twelve-month condition: the appraisal date must be no more than twelve months before the relevant transaction. Twelve months is therefore an outside limit, not a guarantee that a valuation remains usable for the full period. For a pre-revenue therapeutics company, clinical, regulatory, financing, licensing, and pipeline developments can all require reassessment when they may materially affect value.
For these companies, events that may materially affect value include:
Topline results from a clinical trial, whether positive or negative.
A regulatory decision, a designation, or a clinical hold.
A new priced financing round.
A significant licensing, out-licensing, or partnership agreement.
A program discontinuation or a pipeline reprioritization.
A major grant or other non-dilutive award.
Every item on that list is a candidate, not an automatic trigger. The regulatory test is whether later information may materially affect the corporation's value, so the significance of an event depends on the company's facts. A readout that materially changes one company's prospects may have a smaller effect at a company with a broader, more diversified pipeline.
Companies should reassess the valuation when a potentially material event occurs. When necessary, they should involve the appraiser to determine whether the existing analysis still reflects the information now available. The question is not whether an event appears on a checklist; it is whether the existing value remains reasonable in light of the new information. For the general framework on when a 409A valuation needs refreshing, including the material-event standard more generally, see our refresh article.
Cost and Timing
Our typical 409A pricing runs roughly $4,500–$7,500 for early-stage companies and $5,000–$10,000 at growth stage. Late-stage and pre-IPO work runs roughly $12,000–$15,000 or more. For very early-stage companies that have just raised a financing round, Redwood Seed may be available at $2,500. Expedited turnaround carries a premium of roughly 25–50%. Turnaround is typically three to four weeks, measured from receipt of all requested information rather than from signing the engagement letter. Within those ranges, additional financing rounds, complex preferences, licensing terms, and milestone-dependent scenario analysis can increase the amount of valuation work required.
When evaluating an appraiser, look for experience with companies at a similar stage and with clinical, regulatory, financing, and licensing issues that affect the valuation. The appraiser should also be able to explain and defend the analysis in plain language.
Getting Your 409A Right
For your 409A, three questions matter most: how the analysis weighs the latest financing and other evidence, how it reflects milestone-driven outcomes in the allocation, and whether later developments mean the existing valuation still reflects current information. Each answer is company-specific, so the analysis has to stay tied to the evidence rather than to a one-size-fits-all assumption.
The short version:
A recent financing can be an important calibration point. Current value must still reflect all information material to value rather than defaulting to either a stale round price or one prescribed program-valuation technique.
The allocation method should follow the shape of the expected outcomes.
Clinical, regulatory, financing, licensing, and pipeline developments can require reassessment when they may materially affect value. None is an automatic trigger merely because of its category.
Frequently Asked Questions
Can a recent financing be used directly as the common stock value in a 409A valuation?
Not necessarily. A recent arm's-length financing can be an important calibration point. The valuation still has to consider all information material to value and the rights attached to the securities sold. If the transaction is no longer sufficiently informative, current company and market facts may require the analysis to be updated rather than carrying the old price forward.
Does a clinical-stage therapeutics company need to use SBM or PWERM instead of OPM?
No. A scenario-based method can be useful when discrete milestone outcomes are important, while OPM can remain appropriate when its assumptions fit the facts. A hybrid can combine discrete scenarios with OPM allocation within one or more scenarios. Section 409A doesn't prescribe one allocation method for therapeutics companies.
Does a clinical or regulatory milestone automatically require a new 409A valuation?
No. The relevant question is whether the new information may materially affect the company's value. A significant readout, regulatory decision, financing, licensing agreement, or pipeline change should prompt reassessment. The effect depends on the company's facts.
If you'd like to talk through how your last financing, next readout, or another new development affects your grants, we're happy to have that conversation. Learn more about our 409A services | Schedule a consultation | When in doubt, please reach out.